Pharmaceutical

Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia

Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories.

Jul 10, 2024 - 04:00
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories.
Read the original article

Tags:

Previous Article

SciRhom secures $70m for autoimmune diseases treatments

Next Article

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Moving past regulatory obstacles, Protagonist Therapeutics looks to pivotal trial for its rare blood disorder therapy

STAT+: Moving past regulatory obstacles, Protagonist Th...

Jun 14, 2023

Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy

Ipsen outlines $461m for ex-US rights to Day One’s glio...

Jul 26, 2024

Cristália signs licensing deal for Formosa’s APP13007

Cristália signs licensing deal for Formosa’s APP13007

Jan 29, 2024